AnaptysBio Announces Strategic Split into Two Public Companies
Published on 02/06/2026 at 11:01 | Redaktion boerse-global.de
AnaptysBio has confirmed its participation in several upcoming investor conferences, where management will detail a major corporate restructuring. The centerpiece of this strategy is a planned separation of the business into two independent, publicly-traded entities, targeted for completion by the end of 2026.
The company enters this transformative period from a position of financial strength. It anticipates closing its last fiscal year with approximately $300 million in cash and investments. This figure includes a significant one-time $75 million milestone payment from GSK, triggered after the partnered drug Jemperli achieved global net sales of $1 billion. Further financial details and an updated timeline for the separation will be provided when AnaptysBio releases its full fourth-quarter and Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
